Faster recovery after 25G than 20G vitrectomy

Article

But comparable functional and anatomical results in diabetic retinopathy patients

Twenty-five gauge (25G) microincision vitrectomy surgery (MIVS) can produce the same functional prognosis as conventional 20gauge (20G) vitrectomy in patients with proliferative diabetic retinopathy (PDR), but as the procedure is less traumatic for the eye, it reduces postoperative inflammation, induced astigmatism and patient discomfort, it is believed to result in faster recovery time compared with 20G vitrectomy. This means that MIVS has the potential to relieve the financial and temporal burdens of surgical treatment for PDR, representing great progress in the treatment of this complex vitreoretinal condition.

However, despite these advancements and despite the fact that 25G MIVS has now completely replaced 20G vitrectomy in some hospital settings, concrete data about the postoperative recovery period in the cases that underwent 25G MIVS had not previously been available. Therefore, Dr Tatsuhiko Sato (Osaka Rosai Hospital, Japan) and his team conducted a study1 to compare outcomes between the two procedures; specifically, they measured the duration of postoperative hospitalization (chosen as the index of postoperative recovery period) after 25G MIVS and compared it to that following 20G vitrectomy.

The team studied 159 eyes; the first group (n = 72) underwent 20G vitrectomy while the second group (n = 87) underwent 25G vitrectomy. There were no significant differences in patient demographics or preoperative ocular status between the two groups. All procedures were conducted by the same two experienced surgeons, working in a hospital that performs around 1000 vitreoretinal surgeries per year.

The researchers compared the surgical procedures and postoperative functional and anatomical outcomes between the two groups. Patients were permitted to be discharged from hospital when they displayed no signs of infection for five consecutive days after the vitrectomy, had no discomfort and no postoperative complications, such as retinal detachment and nonclearing vitreous haemorrhage. Eyes with vitreous cavities that were still filled with silicone oil at the last examination (baseline + ≥6 months) were classified as anatomical failures.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.